Suffredini Dante A, Xu Wanying, Sun Junfeng, Barea-Mendoza Jesús, Solomon Steven B, Brashears Samuel L, Perlegas Andreas, Kim-Shapiro Daniel B, Klein Harvey G, Natanson Charles, Cortés-Puch Irene
Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland.
Department of Physics and the Translational Science Center, Wake Forest University, Winston-Salem, North Carolina.
Transfusion. 2017 Oct;57(10):2338-2347. doi: 10.1111/trf.14214. Epub 2017 Jun 27.
No studies have been performed comparing intravenous (IV) iron with transfused red blood cells (RBCs) for treating anemia during infection. In a previous report, transfused older RBCs increased free iron release and mortality in infected animals when compared to fresher cells. We hypothesized that treating anemia during infection with transfused fresh RBCs, with minimal free iron release, would prove superior to IV iron therapy.
Purpose-bred beagles (n = 42) with experimental Staphylococcus aureus pneumonia rendered anemic were randomized to be transfused RBCs stored for 7 days or one of two IV iron preparations (7 mg/kg), iron sucrose, a widely used preparation, or ferumoxytol, a newer formulation that blunts circulating iron levels.
Both irons increased the alveolar-arterial oxygen gradient at 24 to 48 hours (p = 0.02-0.001), worsened shock at 16 hours (p = 0.02-0.003, respectively), and reduced survival (transfusion 56%; iron sucrose 8%, p = 0.01; ferumoxytol 9%, p = 0.04). Compared to fresh RBC transfusion, plasma iron measured by non-transferrin-bound iron levels increased with iron sucrose at 7, 10, 13, 16, 24, and 48 hours (p = 0.04 to p < 0.0001) and ferumoxytol at 7, 24, and 48 hours (p = 0.04 to p = 0.004). No significant differences in cardiac filling pressures or performance, hemoglobin (Hb), or cell-free Hb were observed.
During canine experimental bacterial pneumonia, treatment of mild anemia with IV iron significantly increased free iron levels, shock, lung injury, and mortality compared to transfusion of fresh RBCs. This was true for iron preparations that do or do not blunt circulating free iron level elevations. These findings suggest that treatment of anemia with IV iron during infection should be undertaken with caution.
尚无研究比较静脉注射铁剂与输注红细胞(RBC)治疗感染期间贫血的效果。在之前的一份报告中,与较新鲜的细胞相比,输注较陈旧的红细胞会增加感染动物体内游离铁的释放并提高死亡率。我们推测,用输注的新鲜红细胞治疗感染期间的贫血,游离铁释放极少,将被证明优于静脉注射铁剂治疗。
将42只患有实验性金黄色葡萄球菌肺炎并导致贫血的特定品种小猎犬随机分为两组,一组输注储存7天的红细胞,另一组接受两种静脉注射铁剂制剂(7毫克/千克)中的一种,一种是广泛使用的蔗糖铁制剂,另一种是新型制剂铁羧麦芽糖,它可降低循环铁水平。
两种铁剂均在24至48小时时增加了肺泡-动脉氧分压差(p = 0.02 - 0.001),在16小时时加重了休克(分别为p = 0.02 - 0.003),并降低了生存率(输血组为56%;蔗糖铁组为8%,p = 0.01;铁羧麦芽糖组为9%,p = 0.04)。与输注新鲜红细胞相比,通过非转铁蛋白结合铁水平测定的血浆铁在7、10、13、16、24和48小时时随蔗糖铁升高(p = 0.04至p < 0.0001),在7、24和48小时时随铁羧麦芽糖升高(p = 0.04至p = 0.004)。未观察到心脏充盈压或功能、血红蛋白(Hb)或游离血红蛋白有显著差异。
在犬类实验性细菌性肺炎期间,与输注新鲜红细胞相比,静脉注射铁剂治疗轻度贫血会显著增加游离铁水平、休克、肺损伤和死亡率。对于能或不能降低循环游离铁水平升高的铁剂制剂都是如此。这些发现表明,感染期间用静脉注射铁剂治疗贫血应谨慎进行。